Skip to content

Study · In vitro (cells) · 2010

7 results

The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells.

Rennalls LP, Seidl T, Larkin JM, Wellbrock C, Gore ME, Eisen T, Bruno L

Immunology13 Jan 2010Cited by 8 (Europe PMC)

PMID20074207 (opens in a new tab)DOI10.1111/j.1365-2567.2009.03210.x (opens in a new tab)PepBankPUB-20074207
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In human dendritic cells, NDP-MSH significantly reduced the ability of the cells to stimulate allogeneic T cells in mixed lymphocyte reactions.

    In plain wordsIn lab tests, NDP-MSH made human dendritic cells less able to activate donor-mismatched T cells.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseAbility of DCs to stimulate allogeneic T cells
    Study

    humann: not reported in source

    Human dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mixed lymphocyte reactions also revealed that treatment with [Nle(4), DPhe(7)]-alpha-MSH (NDP-MSH), a potent alpha-MSH analogue, significantly reduced the ability of DCs to stimulate allogeneic T cells.
  2. 02LabIn vitro (cells)Activity measurement

    In human dendritic cells, NDP-MSH did not alter surface expression of CD83.

    In plain wordsIn lab tests, NDP-MSH did not change the CD83 marker on human dendritic cells.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeCD83 expression on DCs
    Study

    humann: not reported in source

    Human dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although treatment with NDP-MSH did not alter the expression of CD83 and major histocompatibility complex class I and II, the surface expression of CD86 (B7.2), intercellular adhesion molecule (ICAM-1/CD54) and CD1a was reduced.
  3. 03LabIn vitro (cells)Activity measurement

    In human dendritic cells, NDP-MSH did not alter surface expression of major histocompatibility complex class I.

    In plain wordsIn lab tests, NDP-MSH did not change MHC class I on human dendritic cells.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeMHC class I expression on DCs
    Study

    humann: not reported in source

    Human dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although treatment with NDP-MSH did not alter the expression of CD83 and major histocompatibility complex class I and II, the surface expression of CD86 (B7.2), intercellular adhesion molecule (ICAM-1/CD54) and CD1a was reduced.
  4. 04LabIn vitro (cells)Activity measurement

    In human dendritic cells, NDP-MSH did not alter surface expression of major histocompatibility complex class II.

    In plain wordsIn lab tests, NDP-MSH did not change MHC class II on human dendritic cells.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeMHC class II expression on DCs
    Study

    humann: not reported in source

    Human dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although treatment with NDP-MSH did not alter the expression of CD83 and major histocompatibility complex class I and II, the surface expression of CD86 (B7.2), intercellular adhesion molecule (ICAM-1/CD54) and CD1a was reduced.
  5. 05LabIn vitro (cells)Activity measurement

    In human dendritic cells, NDP-MSH reduced surface expression of CD86 (B7.2).

    In plain wordsIn lab tests, NDP-MSH lowered the CD86 marker on human dendritic cells.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseCD86 (B7.2) expression on DCs
    Study

    humann: not reported in source

    Human dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although treatment with NDP-MSH did not alter the expression of CD83 and major histocompatibility complex class I and II, the surface expression of CD86 (B7.2), intercellular adhesion molecule (ICAM-1/CD54) and CD1a was reduced.
  6. 06LabIn vitro (cells)Activity measurement

    In human dendritic cells, NDP-MSH reduced surface expression of intercellular adhesion molecule ICAM-1 (CD54).

    In plain wordsIn lab tests, NDP-MSH lowered the ICAM-1 marker on human dendritic cells.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseICAM-1 (CD54) expression on DCs
    Study

    humann: not reported in source

    Human dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although treatment with NDP-MSH did not alter the expression of CD83 and major histocompatibility complex class I and II, the surface expression of CD86 (B7.2), intercellular adhesion molecule (ICAM-1/CD54) and CD1a was reduced.
  7. 07LabIn vitro (cells)Activity measurement

    In human dendritic cells, NDP-MSH reduced surface expression of CD1a.

    In plain wordsIn lab tests, NDP-MSH lowered the CD1a marker on human dendritic cells.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseCD1a expression on DCs
    Study

    humann: not reported in source

    Human dendritic cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although treatment with NDP-MSH did not alter the expression of CD83 and major histocompatibility complex class I and II, the surface expression of CD86 (B7.2), intercellular adhesion molecule (ICAM-1/CD54) and CD1a was reduced.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.